The Manufacturers Life Insurance Company Has $487.31 Million Stock Position in Abbott Laboratories $ABT

Key Points

• The Manufacturers Life Insurance Company increased its Abbott Laboratories stake by 5% in the second quarter, bringing its holdings to 5.37 million shares valued at approximately $487.3 million.
• Institutional investors and hedge funds own 75.18% of Abbott’s outstanding shares, with major holders including California State Teachers Retirement System, BlackRock, State Street and Capital International Investors.
• Analysts maintain a generally positive outlook, with Abbott rated a consensus “Moderate Buy” and an average price target of $119.50. The company also exceeded quarterly earnings and revenue estimates, reporting $1.31 in EPS and $12.59 billion in revenue.

The Manufacturers Life Insurance Company lifted its stake in shares of Abbott Laboratories (NYSE:ABT - Free Report) by 5.0% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 5,370,397 shares of the healthcare product maker's stock after purchasing an additional 254,205 shares during the quarter. The Manufacturers Life Insurance Company owned about 0.31% of Abbott Laboratories worth $487,310,000 at the end of the most recent reporting period.

Other institutional investors also recently modified their holdings of the company. California State Teachers Retirement System raised its holdings in shares of Abbott Laboratories by 9,127.1% in the 2nd quarter. California State Teachers Retirement System now owns 246,828,861 shares of the healthcare product maker's stock worth $22,397,251,000 after acquiring an additional 244,153,804 shares during the last quarter. BlackRock Inc. boosted its stake in shares of Abbott Laboratories by 4.6% in the 2nd quarter. BlackRock Inc. now owns 152,563,476 shares of the healthcare product maker's stock worth $13,843,610,000 after buying an additional 6,769,518 shares during the last quarter. State Street Corp lifted its holdings in Abbott Laboratories by 2.1% during the fourth quarter. State Street Corp now owns 79,853,782 shares of the healthcare product maker's stock worth $10,004,880,000 after acquiring an additional 1,627,791 shares during the period. Capital International Investors boosted its position in Abbott Laboratories by 2.6% in the fourth quarter. Capital International Investors now owns 63,229,445 shares of the healthcare product maker's stock worth $7,922,519,000 after purchasing an additional 1,614,706 shares during the last quarter. Finally, J. Stern & Co. LLP grew its stake in Abbott Laboratories by 12,439.6% in the 4th quarter. J. Stern & Co. LLP now owns 39,319,009 shares of the healthcare product maker's stock valued at $4,926,279,000 after purchasing an additional 39,005,451 shares during the period. 75.18% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities analysts recently weighed in on ABT shares. BTIG Research increased their price target on shares of Abbott Laboratories from $131.00 to $134.00 and gave the company a "buy" rating in a research report on Friday, July 17th. Bank of America dropped their price objective on Abbott Laboratories from $120.00 to $102.00 in a research note on Friday, June 12th. Weiss Ratings upgraded Abbott Laboratories from a "sell (d+)" rating to a "hold (c-)" rating in a research note on Thursday, August 6th. JPMorgan Chase & Co. upped their price target on Abbott Laboratories from $110.00 to $120.00 and gave the company an "overweight" rating in a research report on Friday, July 17th. Finally, Wells Fargo & Company raised their price objective on shares of Abbott Laboratories from $109.00 to $112.00 and gave the stock an "overweight" rating in a report on Friday, July 17th. Three investment analysts have rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and four have given a Hold rating to the company. Based on data from MarketBeat, Abbott Laboratories currently has an average rating of "Moderate Buy" and a consensus target price of $119.50.

Abbott Laboratories Price Performance

Shares of NYSE:ABT opened at $103.37 on Friday. The company's fifty day moving average price is $105.46 and its 200-day moving average price is $99.84. The company has a debt-to-equity ratio of 0.57, a current ratio of 1.38 and a quick ratio of 0.97. The firm has a market capitalization of $178.87 billion, a price-to-earnings ratio of 33.45, a PEG ratio of 1.95 and a beta of 0.59. Abbott Laboratories has a one year low of $81.97 and a one year high of $137.49.

Abbott Laboratories (NYSE:ABT - Get Free Report) last announced its earnings results on Thursday, July 16th. The healthcare product maker reported $1.31 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.28 by $0.03. The company had revenue of $12.59 billion during the quarter, compared to analyst estimates of $12.52 billion. Abbott Laboratories had a net margin of 11.65% and a return on equity of 17.69%. The firm's quarterly revenue was up 13.0% compared to the same quarter last year. During the same period in the previous year, the business earned $1.26 earnings per share. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. On average, equities research analysts anticipate that Abbott Laboratories will post 5.52 earnings per share for the current fiscal year.

About Abbott Laboratories

Abbott Laboratories NYSE: ABT is a global healthcare company that develops, manufactures and sells medical products and technologies. Its operations span four principal areas: medical devices, diagnostics, established pharmaceutical products and nutrition. Abbott serves healthcare providers, institutions and consumers in markets around the world.

The company's medical device portfolio includes products for cardiovascular care, diabetes management and other specialties. Its diagnostics business provides laboratory systems, tests and point-of-care solutions, while its nutrition products include infant, child and adult nutritional offerings sold under brands such as Similac, Ensure and Pedialyte.

Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.